← Browse by Condition
Medical Condition

metastatic her2 positive gastroesophageal junction cancer

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 1, Phase 2
NCT06650332 Phase 1, Phase 2
Recruiting

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

Enrollment
90 pts
Location
China
Sponsor
Zhejiang Cancer Hospital
View Trial →